Synapse - Mark Kris

Results (869)

MET inhibitor resistance in patients with MET exon 14-altered lung cancers

Meeting Abstract

Guo, R.; Offin, M.; Brannon, A. R.; Chow, A.; Delasos, L.; Somwar, R.; Wilkins, O.; Scott, K.; Tian, Y.; Cecchi, F.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC

Meeting Abstract

Chaft, J. E.; Costa, D. B.; Muzikansky, A.; Shrager, J. B.; Lanuti, M.; Huang, J.; Ramchandran, K.; Rangachari, D.; Huberman, M.; Piotrowska, Z.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Neoadjuvant atezolizumab in resectable NSCLC patients: Updated clinical and immunophenotyping results from a multicenter trial

Meeting Abstract

Oezkan, F.; He, K.; Owen, D. H.; Pietrzak, M.; Rusch, V. W.; Chaft, J. E.; Kitzler, R.; Nicholas, A.; Schulze, K.; Johnson, A.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Importance of distinguishing adenocarcinoma and squamous cell carcinoma in assessment of pathologic response after neoadjuvant chemotherapy

Meeting Abstract

Emoto, K.; Qu, Y.; Zheng, H.; Aly, R.; Eguchi, T.; Chaft, J.; Tan, K. S.; Kris, M.; Adusumilli, P.; Travis, W.
Modern Pathology (2019)

Fulltext@MSK | Save

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Journal Article

Schoenfeld, A. J.; Arbour, K. C.; Rizvi, H.; Iqbal, A. N.; Gadgeel, S. M.; Girshman, J.; Kris, M. G.; Riely, G. J.; Yu, H. A.; Hellmann, M. D.
Annals of Oncology (2019)

Fulltext@MSK | Save

Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes

Journal Article

Offin, M.; Chan, J. M.; Tenet, M.; Rizvi, H. A.; Shen, R.; Riely, G. J.; Rekhtman, N.; Daneshbod, Y.; Quintanal-Villalonga, A.; Penson, A.; more...
Journal of Thoracic Oncology (2019)

Fulltext@MSK | Save

Importance of distinguishing adenocarcinoma and squamous cell carcinoma in assessment of pathologic response after neoadjuvant chemotherapy

Meeting Abstract

Emoto, K.; Qu, Y.; Zheng, H.; Aly, R.; Eguchi, T.; Chaft, J.; Tan, K. S.; Kris, M.; Adusumilli, P.; Travis, W.
Laboratory Investigation (2019)

Fulltext@MSK | Save

High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden

Journal Article

Benayed, R.; Offin, M.; Mullaney, K.; Sukhadia, P.; Rios, K.; Desmeules, P.; Ptashkin, R.; Won, H.; Chang, J.; Halpenny, D.; more...
Clinical Cancer Research (2019)

Fulltext@MSK | Save

Adrenal metastasectomy in the presence and absence of extraadrenal metastatic disease

Journal Article

Russo, A. E.; Untch, B. R.; Kris, M. G.; Chou, J. F.; Capanu, M.; Coit, D. G.; Chaft, J. E.; D'Angelica, M. I.; Brennan, M. F.; Strong, V. E.
Annals of Surgery (2019)

Fulltext@MSK | Save

MET IHC is a poor screen for MET amplification or MET exon 14 mutations in lung adenocarcinomas: Data from a tri-institutional cohort of the Lung Cancer Mutation Consortium

Journal Article

Guo, R.; Berry, L. D.; Aisner, D. L.; Sheren, J.; Boyle, T.; Bunn, P. A. Jr; Johnson, B. E.; Kwiatkowski, D. J.; Drilon, A.; Sholl, L. M.; more...
Journal of Thoracic Oncology (2019)

Fulltext@MSK | Save